Xilio Therapeutics, Inc. (XLO) compared with its closest peers (RNXT, SDEV, CLNN, CNTX, IBO). Peer set by Business model: Biotech (Clinical / Commercial-Stage); 10 closest by market cap; US-domiciled. First-party data.
| Company | Market Cap | P/E |
|---|---|---|
| RenovoRx, Inc. (RNXT) | $59.31M | — |
| Stablecoin Development Corp (SDEV) | $58.21M | 0.1 |
| Clene Inc. (CLNN) | $56.15M | -2.2 |
| Context Therapeutics Inc. (CNTX) | $54.75M | -3.9 |
| Impact BioMedical Inc. (IBO) | $51.75M | 65.6 |
| TransCode Therapeutics, Inc. (RNAZ) | $50.20M | -0.1 |
| Hyperion DeFi, Inc. (HYPD) | $47.90M | 14.6 |
| Tenax Therapeutics, Inc. (TENX) | $46.42M | -9.1 |
| Grace Therapeutics, Inc. (GRCE) | $46.28M | -9.9 |
| FILANA THERAPEUTICS, INC. (FLNA) | $46.27M | — |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.0 |
XLO overview · XLO earnings · XLO financials · XLO KPIs · XLO investor relations · XLO ownership · XLO filings
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.